C (2:57)

One thing on those 100 candidates, balderdash. There's no way they had a hundred candidates. I mean, what's its expression in football?

B (3:05)

They wrote a list with 100 people on it.

C (3:06)

Right, right. If you have two quarterbacks, you have no quarterback. If I took that seriously, that they really had 100 people interview, that means they had no clue what they wanted. I'm going to give the benefit of the doubt to the board that maybe they had a list of 100 people, but they didn't really consider 100 people there. To me, that would be more scary than positive.

B (3:26)

Rachel, we're going to look back on this Iger tenure, especially the last decade, positively.

A (3:32)

I think so. And I agree with Lou. I think you have to look at both tenures together. I mean, you think of that first one, right? From 05 to 2020, I mean, there was really a series of very transformative acquisitions that formed the company we know today. You think of the acquisitions of Pixar, Marvel, Lucasfilm. You know, this really built that modern Disney content engine that we know. I mean, Iger grew Disney's market cap from about 56 billion to more than 230 billion during that initial run. And then you look in these last few years, you know, he returned in late 2022 to replace Bob Chapek, and really that second stint has been focused on stabilizing the company. Right. You know, so he implements about $5.5 billion in cost cuts, really working to achieve streaming profitability. A lot of challenges that the company has faced during that time, including the Hollywood labor strikes. And so I think that a lot of the last few years has been more about stabilization than some of the growth that investors had come to expect in prior years. One thing I'll note, I mean, Iger's planning to remain senior advisor and board member through the end of 2026 to mentor new leadership. And presumably that might help the company to avoid some of the mistakes, if you will, that occurred during the Czepek era. So I think that's something that investors should feel pleased with as they're looking at this transition. I think it's a much better thought out, well planned, orderly transition than perhaps we saw before.

B (4:56)

Lou, let's look forward now. We do know that tomorrow is coming from the parks. Czapek, by the way, also came from the parks, which that was one thing that I noticed when I went, ah, we already tried this once. Do we really want to do this again? But it does seem, you're right, it does seem like the linear business and the streaming business at least sort of makes sense now. Back back then, back in 2019, 2020, it was. Disney was a rocket ship, but they obviously overbuilt. You had all this confusion during the pandemic. But now we know that, look, the parks is the core of the business. Now the question is, what happens to the rest of the business? What happens to these linear networks? In particular, what happens to espn? Where do you think Disney goes from here?

C (5:40)

Yeah. So here's a bold prediction. I can't imagine Disney without the studio. So I'm not going to go as far as like, you know, a total spinoff.

B (5:47)

Which. Which studio? All the Disney studios, the production, because.

C (5:51)

There'S so much tie in. I mean, maybe they just do it with alliances, but some form of a media spin out. I think definitely espn, maybe Hulu and abc. You know, we've talked a lot about what's going on with Warner Brothers Discovery and about the limited number of chess pieces. I think there's more chess pieces than we know. I think the Disney of the future is going to be somehow more streamlined. We talked about the stock. Stock has done nothing for years with all of these great assets. And it really feels like whether we're talking about ge, whether we're talking about so many of these companies that it's time to wonder is the sum of the parts, you know, trailing the valuation of the whole. Maybe they do go with everything and just forming, you know, some sort of perpetual marketing agreements so they can use the IP of, of the studios and the parks. But I really think that there's going to be some sort of a spin out of media or some sort of a separation of Disney. I'm going to say we're going to hear something about this in the next couple of years, but definitely in the next five years.

B (6:54)

Yeah, if we look back on the early Bob Iger tenure, a lot of those big moves that he made buying Pixar, buying Marvel, was done in the first couple of years. I think Pixar, it sounds like he made that call to Steve Jobs basically as soon as he got the job, so the wheels were spinning there. It will be interesting to see what tomorrow does. When we come back, we are going to talk about Chipotle and why people are eating out less. You're listening to Motley Fool Money.

D (7:20)

Support for the show comes from Fundrise. Investing in companies already in The S&P 500 can sometimes feel like you're being served someone else's leftovers. It's still a great meal, but it's hard not to imagine what the food tasted like when it was fresh out of the oven. Historically, only venture capital investors were served access to the best tech companies in the world that had not gone public yet. And that meant the rest of the world simply had to sit on their hands and wait for an ipo. Fundrise says they're completely upending that dynamic with its new venture capital product. With just a $10 minimum investment, Fundrise's mission is to give everyone the access required to invest in the best tech and AI companies before they go public. There's nothing wrong with leftovers, but now, if you want with fundrise, you can take a seat at the table alongside the biggest names in tech investing. Visit fundrise.com fool to check out Fundrise's venture portfolio and start investing in minutes. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. This is a paid advertisement.

B (8:24)

Welcome back to Motley Fool Money. Chipotle's results were reported last night and they left a lot to be desired in a lot of ways. Rachel, what should we take from this quarter? At Chipotle, we had a lot of negative comps, but this is. This seems like a theme with a lot of restaurant stocks right now.

A (8:40)

Yeah, there's certainly a theme that we're seeing with a lot of these fast, casual chains. So for chipotle, transactions in Q4 dropped by about 3.2%. And this is as we're seeing consumers, particularly Those in the 25 to 35 age group, that's really a core cohort for Chipotle as well as those earning under 100k annually. Those are people that are really pulling back on discretionary spending. So operating margins actually fell a bit compared to a year ago, down to 14.1%. We're also in a time where rising beef, avocado and labor costs that the company's chosen not to fully offset or impacting margins there, they slightly beat on earnings per share. They were marginally ahead of the consensus estimates for revenue. That was up about 5% year over year. They're still growing aggressively. You know, they opened about 132 new restaurants in Q4 alone. They're looking to open up to 370 new locations in 2026. A few things that I think we should note kind of looking at this space, I mean, Chipotle is dealing with issues that some of its rivals are as well. You know, Sweet Gray and Kava are a few that come to mind. We're seeing kind of a shift in how consumers are approaching restaurant spending. We're seeing some of these sit down chains. Think of, you know, Darden restaurants they own, Olive Garden, Texas Roadhouse are gaining market share. I think consumers are becoming increasingly picky about where they're going to put their money to work. And sometimes they're prioritizing those sit down experiences. At the same time. McDonald's has been actually holding pretty steady in terms of their growth. Taco Bell's been a standout performer within Yum brands. Starbucks is even showing some improvements. So systematic challenges in the industry at large. Chipotle I think is dealing with more broader industry headwinds than company specific issues. But I would not expect this to resolve in the next few quarters.

B (10:23)

Lou, one of the things I'm looking at with restaurant stocks is how many times did they mention GLP1s in Chipotle's call? They mentioned it twice and it was actually in relation to their new protein bowl. Bowl of chicken for $3.80.

C (10:37)

Yeah, they invented the nugget.

B (10:39)

Yeah, it's the, the new version of the nugget. Slightly healthier than a nugget, maybe. But it is interesting that that seemed to be their answer not only to GLP1s but also people spending less saying hey, if you just want to spend four bucks on some chicken, come here.

C (10:54)

Yeah, it's a weird time because Rachel's right. Some of this does seem to be just maybe stress on the consumer. I think it kind of makes sense that if the consumer is stressed, they still do planned night outs or special occasion and you still on the fly. But that middle ground where you could go home and cook or save a little money, but you know, you may just get carry out or something that that fast casual is what's suffering. I do wonder though. I mean that implies it's short term. I do wonder if some of this is. We're just so saturated. We've talked about this before. This category didn't exist when I was growing up. It is, you know, from scratch and it has been nothing but growth. Maybe we've reached the natural limit to this market and we have a lot of competitors here. So maybe this speaks to kind of a longer term problem. What I do know, fourth straight quarter of traffic declines. The good news is they are forecasting flat same store sales in 2026, which would be better than down down in 2025. Travis, last time they were down was the E. Coli scandal a decade ago. So, you know, which by the way.

B (12:01)

Was a great buying opportunity.

C (12:03)

It was that time because they were young. Here's my question. I mean, they're talking about growth overseas. That's the big thing. Maybe Middle east wants this. Singapore, South Korea and yes, Mexico. I don't know if that's going to be the path forward. The way from say 2016 to 2025 things improve. You're still paying 30 times forward earnings for a mature business period. Okay. And you know, I'd rather get a burrito bowl right now from them than get a share of the stock. I, I like the company. I just. The growth phase is over and what are you left with?

B (12:41)

It will be very interesting to see what happens not only with Chipotle, but with restaurants in general. We'll have another few earnings reports coming out in the next few weeks and GLP1s are going to be a topic. And Speaking of those GLP1s, they're not all great for even the pharmaceutical companies. We'll get to that in a moment. You're listening to Motley Fool.

C (12:58)

Money.

D (12:59)

Quince is all about elevated essentials that feel effortless. Designed for layering and mixing, each piece helps build a timeless wardrobe made to last. With versatile silhouettes and thoughtful details. They're the kind of styles you'll wear again, again and again. Quince uses the highest quality materials, like 100% European linen and organic cotton. Everything is built to hold up season after season. The stitching, the fit, the fabrics, these are pieces you'll reach for over and over again. I can tell you I'm not the only fan of Quint's in my house. As much as I love my long sleeve cotton tees and their polos, my son is an even bigger fan of their 100% cotton joggers. Refresh your wardrobe with quince. Go to quints.com motley for free shipping on your order and 365 day returns. Now available in Canada too. That's Q-U-I-N-C-E.com motley to get free shipping and 365 day returns. Quints.com motley.

B (13:55)

Welcome back to Motley Fool Money. The GLP1 craze was started by Eli Lilly and Novo Nordisk are really the two companies that are associated with this. But Rachel, Novo Nordisk took a huge hit in the market and they're actually expecting a decline in the business. What is the story behind this? It seems like GLP1 should be just growing forever, but it seems like the competitive dynamics are really changing there.

A (14:21)

Yeah, this is really a tale of two very different businesses. I mean, you think about Novo Nordisk, they had a much kind of slower growing insulin business before they enjoyed the boom from their GLP1 success. Eli Lilly had a much more kind of established, broader, diverse range of products that they were selling in a much more profitable foundation from which to launch into that growth. And we are seeing a real disparity in how these two companies are performing. So Novo Nordisk, they're targeting anywhere from a 5 to 13% decline in sales and profits for 2026. They've said that the most favored nation pricing deal they reached with the Trump administration has been impactful here. But there's a lot of factors here as well. You've got key patents for Semaglutide, that's the active ingredient in Ozempic and Wegovy. Those are expiring in major international markets soon, including China, Canada and Brazil. There's of course, the loss of market share to key rivals like Eli Lilly, but also some of the cheaper, copycat, if you will, compounded versions of its drugs. The CEO is saying this is going to be a very challenging year. So all of that does not bode particularly well for the company. Now contrast that, you've got Eli Lilly, they had record results. They're looking for their full year revenue to rise as much as 25% in 2026. Meanwhile, even as Novo Nordisk they launched their oral Semaglutide, Eli Lilly is looking for approval for their next generation weight loss pill in mid-2026. That's broadly expected to really cannibalize a lot of the sales in the market. They had a 43% revenue increase in Q4 alone. They saw sales of their key GLP1 drugs both jump by more than 100%. And Eli Lilly became the first pharma company to surpass a $1 trillion market cap in 2025. So, yes, there are some industry specific challenges, but I think the issues that Novo Nordisk is facing are much more specific to that business.

C (16:11)

Yeah, who knew? It's a terrible joke here. Who knew? The GLP1s were slimming for Novo Nordisk.

D (16:18)

Right.

C (16:18)

But does anyone not have a GLP1 at this point? It feels like Rachel said, yeah, and.

B (16:25)

There'S more coming to the market over the next couple of years, too.

C (16:28)

Pricing headwinds in an increasingly competitive market. How many times was that set? You know, you talk about the restaurant stocks. How often was GLP1 said in their calls, how often was just pricing headwinds set on the Norvo? The oral was supposed to be the solution here, but if you look at it, it's 2.4mg versus 25mg for the oral. That's 10x the amount of active ingredient. I'm curious. We're seeing margins fall. How much of that is just startup here and how much of that is somewhat permanent? If they do, quote, unquote, succeed in moving people to the oral version, what does that do to profitability? That seems like a slippery slope as far as that being the answer. I don't know if Novo has a good answer right here. And as you say, it's only going to get more competitive from here. I get the market's reaction.

B (17:18)

Again, another thing that is going to be fascinating to follow because this has been a huge growth story for a number of different companies and a lot of speculation behind some of the new GLP1s that are that are coming. But yeah, like Lou said, if you're coming into a very competitive market, maybe it's not the best to be those producers which are having margin pressure, even if you have higher volume. As always, people on the program may have interest in the stocks they talk about, and the Motley fool may have formal recommendations for or against. So don't buy or sell stocks based solely on what you hear. All personal finance content follows the Motley Fool's editorial standards and is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes for Lou Whiteman, Rachel Warren, Dan Boyd and Christy Waterworth. Behind the glass, I'm Travis Hoyam. We'll see you here tomorrow.